Allergy Notes, Evidence-based Information by Board-certified Physicians

A Game-Changer for Multi-Food Allergies? Omalizumab Matches Oral Immunotherapy's Long-Term Success - With Far Less Hassle

Biologics vs. JAK Inhibitors for Atopic Dermatitis: Which One Wins for Your Patient? A 2026 Practical Guide

2025: A Breakthrough Year for Chronic Urticaria - New FDA Approvals Reshaped Treatment

Tezepelumab in Real-World Danish Severe Asthma Study: Benefits Even After Biologic Switches

Tezepelumab vs. Dupilumab in Severe Asthma: Head-to-Head Real-World Data Shows No Clear Winner

Omalizumab Helps High-Risk Patients Tolerate Honeybee Venom Allergy Shots

Dupilumab-Induced Eosinophilia (DIBE) in CRSwNP Affected 48% of Patients

Why Some Chronic Hives Patients May Not Respond Well to Omalizumab: New Biopredictors Identified

Chronic Urticaria: Making Breakthroughs if Managing a Challenging Disease

Hope for Some Alpha-Gal Patients: In-home Graded Protocol

Are These New Biologics Game-Changers or Just More of the Same?

The Esophagus: Not Just a Tube, But a Smart Immune Organ

Artificial intelligence in Allergy and Immunology - JACI review

Staph Aureus on the Skin Associated With Severe Food Allergic Reactions Via a Cascade: IL-33, IL-3, IL-4

Predicting Outcomes in Common Variable Immunodeficiency (CVID)

New Risk Score Predicts Nasal Polyp Recurrence After Sinus Surgery for CRSwNP